Cardiotoxicity

The grounding supports exposure to cardiotoxic cancer treatments as the cause, especially chemotherapy, immune therapies, and radiation. Immune checkpoint inhibitors and CAR-T cell therapies are specifically associated with cardiovascular adverse events. No other causes are supported by the supplied material.

The mechanism depends on the exposure, but the supplied literature emphasizes subclinical ventricular dysfunction and reduced left ventricular function as early manifestations. For immune checkpoint inhibitors, dysregulation of immune checkpoints such as PD-1/PD-L1 and CTLA-4 can trigger aberrant T-cell activation against cardiac self-antigens, leading to myocarditis and vasculitis. Immune therapies can also produce systemic inflammatory toxicity, including cytokine release syndrome, with downstream cardiovascular consequences.

The grounding supports exposure to potentially cardiotoxic cancer therapies as the main risk factor. It also indicates that immune checkpoint inhibitor-related cardiovascular events can be unpredictable in timing. No patient-level demographic or clinical risk factors are supported by the supplied material.

The supplied material supports prevention, monitoring, diagnosis, and therapy within cardio-oncology rather than a single treatment approach. For chemotherapy-related cardiotoxicity, echocardiographic left ventricular global longitudinal strain is used for early prediction of subclinical dysfunction. For immune therapy-related cardiotoxicity, management is framed around recognition of immune-related cardiovascular adverse events and cardio-oncology monitoring and prevention protocols; no specific drug-class treatment strategy is supported beyond this.